CBD Global Sciences Inc. (CBDNF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CBD Global Sciences Inc. (CBDNF) trades at $0.0419 with AI Score 38/100 (Grade D). CBD Global Sciences Inc. is involved in the cannabidiol (CBD) industry, focusing on farming, processing, and product manufacturing. Market cap: $2.07M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CBDNF: CBDNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBDNF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
CBD Global Sciences Inc. (CBDNF) Healthcare & Pipeline Overview
CBD Global Sciences Inc. operates in the CBD market, engaging in farming, processing, and manufacturing CBD products. With brands like Aethics and CannaOil, the company caters to the growing demand for CBD-based solutions, facing competition and regulatory challenges in the evolving healthcare landscape.
What Is the Investment Thesis for CBDNF?
Investing in CBD Global Sciences Inc. presents a high-risk, high-reward scenario. The company's negative P/E ratio of -0.20 and a significantly negative profit margin of -3469.4% indicate substantial financial challenges. A gross margin of 24.6% suggests some ability to generate profit from sales, but operational inefficiencies weigh heavily. The company's beta of 0.43 suggests lower volatility compared to the market. Growth depends on successful brand building, market penetration, and navigating regulatory hurdles. Key catalysts include potential changes in legislation that could broaden market access and increased consumer acceptance of CBD products. The company's ability to scale operations efficiently and achieve profitability will be critical for long-term success.
Based on FMP financials and quantitative analysis
CBDNF Key Highlights
- Market capitalization of $2.07M indicates the company's small size and potential for growth, but also higher risk.
- Negative P/E ratio of -0.20 reflects the company's current lack of profitability.
- Profit Margin of -3469.4% highlights significant operational challenges and high expenses relative to revenue.
- Gross Margin of 24.6% suggests potential for profitability if operational efficiencies are improved.
- Beta of 0.43 indicates lower volatility compared to the overall market.
Who Are CBDNF's Competitors?
CBDNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| EMBC Embecta Corp. | $3.44 | +5.85% | $204M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDNF's Key Strengths?
- Established brands: Aethics, CannaOil, and Strasburg Pharms.
- Vertically integrated operations.
- Proprietary formulations for CBD products.
What Are CBDNF's Weaknesses?
- Negative profitability and high operating expenses.
- Small market capitalization.
- Limited financial resources.
What Could Drive CBDNF Stock Higher?
- Potential changes in legislation that could broaden market access for CBD products.
- Increasing consumer acceptance of CBD products for wellness and therapeutic applications.
- Expansion of distribution networks and partnerships with retailers.
- Potential for new product launches and innovative formulations.
- Research and development efforts to explore new therapeutic applications of CBD.
What Are the Key Risks for CBDNF?
- Financial-distress signal — its Altman Z-Score of -29.39 sits in the distress zone (elevated bankruptcy risk).
- Regulatory uncertainty and evolving legal landscape.
- Intense competition from established and emerging players.
- Fluctuations in raw material prices.
- Changing consumer preferences and market trends.
- Negative profitability and high operating expenses.
What Are the Growth Opportunities for CBDNF?
- Expansion into new therapeutic areas represents a significant growth opportunity for CBD Global Sciences Inc. The company can invest in research and development to explore the potential of CBD in addressing specific health conditions, such as anxiety, pain management, and sleep disorders. Positive clinical trial results and subsequent regulatory approvals could lead to the development of novel CBD-based therapies, opening up new revenue streams and market segments. This expansion requires strategic partnerships with research institutions and healthcare providers.
- Geographic market expansion offers another avenue for growth. CBD Global Sciences Inc. can target new regions with favorable regulatory environments and growing consumer demand for CBD products. This expansion could involve establishing distribution networks, partnering with local retailers, or setting up operations in new countries. Careful market research and adaptation of product offerings to local preferences are essential for success.
- Development of innovative CBD product formulations can drive revenue growth. CBD Global Sciences Inc. can invest in research and development to create new and improved CBD products, such as enhanced edibles, topical creams, and transdermal patches. These innovative products can cater to specific consumer needs and preferences, differentiating the company from competitors. Collaborations with formulation experts and technology providers can accelerate the development process and ensure product quality and efficacy.
- Strategic partnerships with established healthcare companies can provide access to new markets and distribution channels. CBD Global Sciences Inc. can collaborate with pharmaceutical companies, nutraceutical manufacturers, or healthcare providers to co-develop and market CBD products. These partnerships can leverage the expertise and resources of established players, accelerating market penetration and building brand credibility. Due diligence and careful negotiation are essential to ensure mutually beneficial partnerships.
- Focus on sustainable and ethical sourcing of CBD can enhance brand reputation and attract environmentally conscious consumers. CBD Global Sciences Inc. can implement sustainable farming practices, obtain certifications for organic and fair-trade CBD, and promote its commitment to environmental stewardship. This focus on sustainability can differentiate the company from competitors and appeal to a growing segment of consumers who prioritize ethical and environmentally responsible products. Transparency and traceability throughout the supply chain are crucial for building trust with consumers.
What Opportunities Does CBDNF Have?
- Expansion into new therapeutic areas.
- Geographic market expansion.
- Development of innovative CBD product formulations.
- Strategic partnerships with established healthcare companies.
What Threats Does CBDNF Face?
- Regulatory uncertainty and evolving legal landscape.
- Intense competition from established and emerging players.
- Fluctuations in raw material prices.
- Changing consumer preferences and market trends.
What Are CBDNF's Competitive Advantages?
- Brand recognition through Aethics, CannaOil, and Strasburg Pharms brands.
- Vertically integrated operations, controlling aspects of the supply chain from cultivation to product distribution.
- Proprietary formulations and manufacturing processes for CBD products.
What Does CBDNF Do?
CBD Global Sciences Inc., established in 2018 and headquartered in Lakewood, Colorado, operates within the cannabidiol (CBD) sector. The company's core business revolves around CBD farming, processing, and the manufacturing of a diverse range of CBD products. These products are marketed under several brand names, including Aethics, CannaOil, and Strasburg Pharms. The company cultivates biomass, extracts CBD oil, and formulates various CBD-infused products aimed at capitalizing on the increasing consumer interest in CBD for wellness and therapeutic applications. CBD Global Sciences seeks to establish a vertically integrated operation, controlling aspects of the supply chain from cultivation to product distribution. The company aims to differentiate itself through product quality, branding, and strategic partnerships within the evolving CBD market.
What Products and Services Does CBDNF Offer?
- Farming of cannabidiol (CBD) biomass.
- Processing of CBD biomass to extract CBD oil.
- Manufacturing of CBD oil products.
- Marketing and sales of CBD products under the Aethics brand.
- Marketing and sales of CBD products under the CannaOil brand.
- Marketing and sales of CBD products under the Strasburg Pharms brand.
How Does CBDNF Make Money?
- Cultivation of hemp to produce CBD-rich biomass.
- Extraction and refinement of CBD oil from the biomass.
- Formulation and manufacturing of various CBD products, including oils, tinctures, edibles, and topicals.
- Distribution and sale of CBD products through online channels, retail partnerships, and wholesale agreements.
What Industry Does CBDNF Operate In?
CBD Global Sciences Inc. operates within the rapidly evolving CBD industry, a segment of the broader healthcare market. The industry is characterized by increasing consumer demand for CBD products, driven by perceived wellness benefits. However, the market is also highly competitive, with numerous players vying for market share. Regulatory uncertainty remains a significant challenge, as laws governing CBD production, distribution, and marketing vary widely across jurisdictions. The company faces competition from established players in the pharmaceutical, nutraceutical, and consumer goods industries, as well as smaller, specialized CBD companies. Success in this market requires effective branding, product innovation, and navigating the complex regulatory landscape.
Who Are CBDNF's Key Customers?
- Consumers seeking CBD products for wellness and therapeutic purposes.
- Retailers and distributors of CBD products.
- Wholesale customers, including healthcare providers and other businesses.
F-Score 5/9Financial Health
CBD Global Sciences Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -29.39 places it in the distress zone, a signal of elevated financial risk.
ROE 116%Key Financial Metrics
Return on equity for CBD Global Sciences Inc. stands at 116.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -73.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching.
CBD Global Sciences Inc. (CBDNF) Valuation Context
Valued at $2.07M, CBDNF is classified as a micro-cap stock. Relative to its peer group, CBDNF's quantitative score of 38/100 is below the peer average of 63/100.
CBDNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established brands: Aethics, CannaOil, and Strasburg Pharms.
- Vertically integrated operations.
- Proprietary formulations for CBD products.
- Upcoming: Potential changes in legislation that could broaden market access for CBD products.
Bear Case
- Negative profitability and high operating expenses.
- Small market capitalization.
- Limited financial resources.
- Ongoing: Regulatory uncertainty and evolving legal landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CBDNF Latest News
No recent news available for CBDNF.
CBDNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDNF.
Price Targets
Wall Street price target analysis for CBDNF.
CBDNF MoonshotScore
What does this score mean?
The MoonshotScore rates CBDNF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Brad Wyatt
CEO
Brad Wyatt serves as the CEO of CBD Global Sciences Inc. His background includes experience in the cannabis and hemp industries, with a focus on business development and strategic partnerships. He has been involved in various aspects of the industry, from cultivation to product manufacturing and distribution. Wyatt's expertise lies in identifying market opportunities, building relationships with key stakeholders, and driving revenue growth. He has a track record of successfully launching new products and expanding market share in the competitive CBD market.
Track Record: Under Brad Wyatt's leadership, CBD Global Sciences Inc. has focused on expanding its product portfolio and distribution network. Key achievements include the development of new CBD product formulations and the establishment of partnerships with retailers and distributors. The company has also worked to enhance its brand recognition and build a loyal customer base. Wyatt has overseen the company's efforts to navigate the complex regulatory landscape and ensure compliance with all applicable laws and regulations.
CBDNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CBDNF may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, defunct businesses, or companies with questionable operations.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in CBDNF.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or manipulation is higher on the OTC market.
- OTC Other tier stocks are subject to less regulatory oversight.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's liquidity and trading volume.
- Consult with a qualified financial advisor.
- The company has been in operation since 2018.
- The company has established brands: Aethics, CannaOil, and Strasburg Pharms.
- The company has a CEO in place.
CBD Global Sciences Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for CBDNF?
CBDNF holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. CBD Global Sciences Inc. is involved in the cannabidiol (CBD) industry, focusing on farming, processing, and product manufacturing. The company offers a range of CBD products under various brand …
What does CBD Global Sciences Inc. do?
CBD Global Sciences Inc. is a cannabidiol (CBD) company involved in the farming, processing, and manufacturing of CBD products. The company cultivates hemp, extracts CBD oil, and formulates various CBD-infused products, including oils, tinctures, edibles, and topicals. These products are marketed under the Aethics, CannaOil, and Strasburg Pharms brand names.
What do analysts say about CBDNF stock?
There is currently no available analyst coverage for CBDNF stock. The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own thorough research and due diligence before investing in CBDNF. Key valuation metrics, such as P/E ratio and profit margin, indicate significant financial challenges.
What are the main risks for CBDNF?
CBD Global Sciences Inc. faces several key risks, including regulatory uncertainty, intense competition, fluctuations in raw material prices, and changing consumer preferences. The evolving legal landscape surrounding CBD products creates uncertainty and potential compliance challenges. The company operates in a highly competitive market with numerous players vying for market share. Fluctuations in hemp prices can impact the company's profitability.
What are the key factors to evaluate for CBDNF?
CBD Global Sciences Inc. (CBDNF) holds an AI score of 38/100 (low). Not financial advice.
How frequently does CBDNF data refresh on this page?
CBDNF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CBDNF's recent stock price performance?
CBD Global Sciences Inc. (CBDNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brands: Aethics, CannaOil, and Strasburg Pharms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBDNF overvalued or undervalued right now?
CBD Global Sciences Inc. (CBDNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CBDNF before investing?
Before investing in CBD Global Sciences Inc. (CBDNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may be outdated or incomplete.